Literature DB >> 16359508

Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.

J M Brugge1, P Simioni, F Bernardi, D Tormene, B Lunghi, G Tans, A Pagnan, J Rosing, E Castoldi.   

Abstract

BACKGROUND: Functional defects of the protein C pathway, detectable in plasma as activated protein C (APC) resistance, are a prevalent risk factor for venous thrombosis. The factor V (FV) Leiden mutation causes APC resistance by interfering with the APC-mediated inactivation of both FVa and FVIIIa. Co-inheritance of FV Leiden and quantitative FV deficiency on different alleles, a rare condition known as pseudo-homozygous APC resistance, is associated with pronounced APC resistance and 50% reduced FV levels, because of non-expression of the non-Leiden FV allele.
OBJECTIVES: The role of normal FV in modulating the APC resistance phenotype in carriers of FV Leiden was investigated in patients with pseudo-homozygous APC resistance and in model systems. PATIENTS/
METHODS: Four functional plasma assays probing both components of APC resistance (susceptibility of FVa to APC and cofactor activity of FV in FVIIIa inactivation) were employed to compare seven clinically and genetically characterized FV Leiden pseudo-homozygotes to 30 relatives with different FV genotypes (including 12 FV Leiden heterozygotes and seven carriers of FV deficiency) and to 32 unrelated FV Leiden homozygotes. RESULTS AND
CONCLUSIONS: All assays consistently indicated that FV Leiden pseudo-homozygotes are significantly more APC-resistant than heterozygotes and indistinguishable from homozygotes. Thrombin generation measurements in FV-deficient plasma reconstituted with purified normal FV and FV Leiden confirmed these observations and showed that the expression of the normal FV allele is an important modulator of APC resistance in FV Leiden heterozygotes. These findings provide an explanation for the higher thrombotic risk of FV Leiden pseudo-homozygotes when compared with heterozygotes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16359508     DOI: 10.1111/j.1538-7836.2005.01634.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

Review 1.  Progress in research into the genes associated with venous thromboembolism.

Authors:  Lian-Xing Zhao; Bo Liu; Chun-Sheng Li
Journal:  World J Emerg Med       Date:  2015

2.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

3.  Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury.

Authors:  Hunter B Moore; Ernest E Moore; Eduardo Gonzalez; Kirk C Hansen; Monika Dzieciatkowska; Michael P Chapman; Angela Sauaia; Bernadette West; Anirban Banerjee; Christopher C Silliman
Journal:  Shock       Date:  2015-01       Impact factor: 3.454

4.  A novel factor V mutation causes a normal activated protein C ratio despite the presence of a heterozygous F5 R506Q (factor V Leiden) mutation.

Authors:  Florian Prüller; Reinhard B Raggam; Harald Mangge; Martie Truschnig-Wilders; Eva-Maria Matzhold; Eva-Christine Weiss; Barbara Hasiba; Kelli L Summers; Wilfried Renner; Gabriele Siegert; Heike Kostka
Journal:  Br J Haematol       Date:  2013-08-19       Impact factor: 6.998

5.  Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation.

Authors:  Sanne L N Brouns; Johanna P van Geffen; Elena Campello; Frauke Swieringa; Paolo Simioni; Johan W M Heemskerk; Luca Spiezia; René van Oerle; Isabella Provenzale; Remco Verdoold; Richard W Farndale; Kenneth J Clemetson; Henri M H Spronk; Paola E J van der Meijden; Rachel Cavill; Marijke J E Kuijpers; Elisabetta Castoldi
Journal:  Sci Rep       Date:  2020-07-17       Impact factor: 4.379

6.  Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation.

Authors:  M Ibrahim-Kosta; P Suchon; F Couturaud; D Smadja; R Olaso; M Germain; N Saut; L Goumidi; C Derbois; F Thibord; S Debette; P Amouyel; J F Deleuze; P van Doorn; E Castoldi; E Patin; M C Alessi; D A Trégouët; P E Morange
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.